|
|
|
|
|
|
|
M T W Th Fri |
|
29 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Endpoints has a top-notch crew in Chicago for ASCO, and starting this weekend, we'll have plenty of stories coming out of the conference. Keep it here for all the analysis you need, and be sure to check out our schedule of events! You can register here. |
|
|
|
Alex Hoffman |
Senior Copy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Bayer
|
Third time’s the charm? Replimune announced Fridaythat it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b... | |
|
|
|
|
|
|
|
|
by Lei Lei Wu
|
Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
🔎 AstraZeneca narrows path for failed antibody: The company announced last summerthat its monoclonal antibody anselamimab missed the primary endpoint in a pair of... | |
|
|
|
|
|
